Celgene maintained by Merrill at buy

Celgene Corp. was maintained by Merrill Lynch analyst Thomas McGahren at a buy rating as the company reaffirmed its 2005 earnings-per-share guidance of $0.36 to $0.38 on expected total revenue in the range of $535 million. Both figures are in line with Merrill's estimates of $0.37 and $536 million. Shares of the Summit, N.J., pharmaceutical company were down $2.33, or 3.24%, at $69.55 on volume of 3,829,045 shares versus the three-month running average of 2,345,720 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.